Compare Eli Lilly And Co (LLY) vs Neurocrine Biosciences Inc (NBIX) Price & Performance

Eli Lilly And CoTrade

Neurocrine Biosciences IncTrade

Price performance (Past 24H)

Key statistics

Eli Lilly And Co vs Neurocrine Biosciences Inc — how do they compare? Eli Lilly And Co trades at $1,202.88 (market cap $1.08T), while Neurocrine Biosciences Inc trades at $158.83 (market cap $16.46B). The key difference: Eli Lilly And Co is far larger — about 65.6× Neurocrine Biosciences Inc's market cap, and Eli Lilly And Co pays a 0.57% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.

	LLY	NBIX
Market Cap	$1.08T	$16.46B
Sector	Health	Health
52-Week High	$1.24K	$185.50
52-Week Low	$639.43	$123.10
Enterprise Value	$1.13T	$16.48B
Dividend Yield	0.57%	—

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Eli Lilly And Co

Eli Lilly (LLY) trades at $1,231.58, up 3.87% in the past 24 hours, reflecting strong momentum near its 52-week high. The stock exhibits bullish technical signals with robust fundamentals, including 48% revenue growth in Q2 2026 and a net income margin of 33.53%. Recent news highlights legal actions against black-market drug sales and positive analyst sentiment following earnings beats.

Outlook remains positive with a consensus price target of $1,380, though high valuation ratios (P/E 40.79) and regulatory risks pose challenges. Earnings growth and pipeline advancements, like retatrutide, drive upside potential, but investors should monitor competitive pressures and execution risks.

Neurocrine Biosciences Inc

No Aura AI signal available yet.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

LLY

Eli Lilly sues six U.S. entities over illegal black-market retatrutide sales.PRNewsWire · 8 hours agoNeutral Eli Lilly posts strong Q2 with revenue beat and raises full-year guidance, stock up nearly 10% last week.24/7 Wall Street · 1 day agoBullish Eli Lilly adopts Veeva Vault CRM globally to enhance medicine delivery using AI.PRNewsWire · 1 day agoBullish View details →

NBIX

INGREZZA shows significant quality of life and movement improvements in tardive dyskinesia patients after 24 weeks.PRNewsWire · 5 hours agoBullish View details →

About Eli Lilly And Co

Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer

About Neurocrine Biosciences Inc

Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.